Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 16/20 | 0.54 |
| ▸ | PPARA | Q07869 | 13/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968334 | 0.95 | FFAR1 (0.63) | FFAR1PPARGPPARAKDRPPARD | |
| SCHEMBL6971740 | 0.94 | FFAR1 (0.54) | FFAR1PPARGPPARAKDR | |
| SCHEMBL6960061 | 0.94 | PPARG (0.57) | PPARGPPARAPPARD | |
| SCHEMBL6973891 | 0.91 | KDR (0.60) | FFAR1PPARGPPARAKDR | |
| SCHEMBL6531845 | 0.89 | PPARG (0.61) | FFAR1PPARGPPARAKDR | |
| SCHEMBL6966826 | 0.89 | PPARG (0.50) | FFAR1PPARGPPARA | |
| SCHEMBL6052222 | 0.89 | PPARG (0.50) | FFAR1PPARGPPARA | |
| SCHEMBL6960213 | 0.88 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL4727296 | 0.87 | PPARG (0.47) | FFAR1PPARGPPARAKDRPPARD | |
| SCHEMBL12520669 | 0.87 | PPARG (0.56) | FFAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0783496-B9 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-03 | — | — | EP | claimed |
| EP-0783496-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-0783496-A1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-16 | — | — | EP | claimed |
| WO-1996005186-A1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-22 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0783496-B9 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-0783496-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-5965589-A | AN ACTIVE MATERIAL HAVING HYPOGLYCEMIC ACTIVITY AND BLOOD LIPID LOWERING ACTIVITY, FOR USE AS AN ANTIDIABETIC AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0783496-A1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996005186-A1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | FFAR1 4553/4885PPARG 2274/4885PPARA 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.